Kreiotel-H 40 Tablet contains a combination of Telmisartan 40 mg and Hydrochlorothiazide 12.5 mg, formulated for the management of hypertension. Telmisartan is an angiotensin II receptor antagonist that selectively blocks the binding of angiotensin II to the AT1 receptor, thereby inhibiting vasoconstriction and aldosterone secretion, leading to vasodilation and reduction in blood pressure. Hydrochlorothiazide is a thiazide diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to decreased blood volume and further lowering of blood pressure. The combination of these two agents provides complementary mechanisms to effectively control high blood pressure, reducing the risk of cardiovascular events such as stroke, myocardial infarction, and heart failure. Kreiotel-H 40 is indicated for patients who require multiple antihypertensive agents to achieve optimal blood pressure control. It should be used under medical supervision, with monitoring of electrolyte levels, renal function, and blood pressure. Caution is advised in patients with renal impairment, electrolyte imbalance, or hypersensitivity to sulfonamides. Adverse effects may include dizziness, hypotension, hyperkalemia, or electrolyte disturbances. Patient adherence to prescribed dosage and lifestyle modifications is essential for therapeutic success.